



COLTENE Holding AG Half Year Results – 2008

Media and Analyst Conference Call
Thursday August 21, 2008

Safe Harbour Statement

Before we may start with the presentations, we need to remind you that the information made available in this conference call may include forward-looking statements that reflect the intentions, beliefs or current expectations and projections of COLTENE Holding AG about the future results of operations, financial condition, liquidity, performance and similar circumstances. Such statements are made on the basis of assumptions and expectations which may prove to be erroneous, although COLTENE Holding AG believes them to be reasonable at this time.


Content

- COLTENE – New Dental Standalone
- Strengthened Management
- Dental Business
- Financials
- Outlook
- Q&A

Highlights 1HY2008


- Dental Business – at constant June 2007 translation rates
 - Sales up 8.4% vs. previous year
 - EBIT up 1.5% vs. previous year
- Achieved 1.8 CHFm more in Net Sales in Q2 vs. Q1
- Free cash flow raised by 52% in 1HY2008
- Earnings per share CHF 8.04
- Equity ratio 81%

COLTENE at a glance....today

- April 2008: sale of Medical business (Medisize)
- New Dental stand-alone 
- Clear focus on dentistry, an attractive long-term growth market
- Good profitability and continuously excellent free cash flows
- Strong and solid balance sheet
- Good base for organic growth and acquisitions
- Attractive dividend yield

5


Strengthened Management




* Chairman: Nick Huber
 Members: Robert Heberlein, Matthew Robin, Jerry Sullivan

6

Global Dental Market



Base for COLTENE Growth Strategy



Growth: Achievements in 1HY2008

- Composite curing-lights business grew by >40% YoY (esp. LED lights)
- Rotary instruments business increased by >30% in 1HY08 vs. 1HY07 (esp. CEI carbide burs)
- Strong growth in condensation silicones (+20%) in emerging markets YoY
- Endo line (i.e. fiber posts) grew by 10% YoY
- Successful launch of new bonding material (7th generation One Coat Bond) in 1HY2008

Key Product Successes – 1HY2008



Growth: Achievements (cont.)

- Affinis impression material for implants launched in June 2008 – will leverage A-Silicone business
- Whole range of COLTENE products perfectly matches implantology procedures
 - Affinis impression product family
 - Cool Temp temporary material
 - Jet Blue Bite registration material
 - Para Cem universal cement
 - New implantology brochure showing treatment steps for optimal application


11



IMPLANTOLOGY

Perfect results effortlessly

Precision and working efficiently with first-class materials is in demand. For the benefit of the patient as well as advantageous for dentists and dental technicians.



12

Growth – Geographical Expansion

- Focus on Emerging Markets
 - China: New COLTENE subsidiary successfully started and looking at doubling turnover in 2008
 - India: documents for new subsidiary submitted to the authorities in 1HY2008
 - Russia: active expansion activities led to high double digit growth YoY
 - Evaluation of local manufacturing as well as filling and packaging still ongoing

13

Growth – Focus Acquisition

- Targets identified (short list)
- Working actually at the top 3 projects
- Projects support both
 - product / market emphasis
 - geographical expansion
- Targets need to support direct selling capabilities

14

Further Highlights 1HY2008

- CEI production increased to 3 shifts: gain of >30% in capacity
- Strong increase of market-specific composite (filling material) in Latin America and Eastern Europe
- Strengthened COLTENE brand by positioning the new dental stand-alone company
- Expanded dealer network in emerging markets to support planned growth



15

4th Swiss Symposium on esthetic dentistry

**4th Swiss Symposium
on Esthetic Dentistry**
Stravinsky Auditorium - Montreux
May 15th - 17th 2008



**COLTENE hosted 300
participants at this event**

16

Financials 1HY2008


17

Growth in Net Sales

1'000 CHF	1 HY 08	%	1 HY 07	%	% YoY
Net Sales	81'915	100.0%	81'068	100.0%	1.0%
Raw materials	22'665	27.7%	22'625	27.9%	0.2%
Personnel expenses	29'336	35.8%	27'866	34.4%	5.3%
Other expenses	18'314	22.4%	16'861	20.8%	8.6%
Depreciation&amortization	2'084	2.5%	2'151	2.7%	-3.1%
Total operating expenses	49'734	60.7%	46'878	57.8%	6.1%
EBIT	9'516	11.6%	11'565	14.3%	-17.7%
Net Sales currencies adjusted	87'888	107.3%	81'068	100.0%	8.4%

18

Solid EBIT (TCHF)



19

High Profit for the Period

1'000 CHF	1 HY 08	%	1 HY 07	%	% YoY
EBIT	9'516	11.6%	11'565	14.3%	-17.7%
Financial result (net)	-571	-0.7%	-51	-0.1%	1019.6%
Net profit before tax	8'945	10.9%	11'514	14.2%	-22.3%
Tax expenses	-1'959	-2.4%	-2'836	-3.5%	-30.9%
In % of net profit before tax	21.9%		24.6%		
Net profit cont. operations	6'986	8.5%	8'678	10.7%	-19.5%
Profit discont. operations	29'700	36.3%	3'742	4.6%	693.7%
Profit for the period	36'686	44.8%	12'420	15.3%	195.4%

20

Excellent Free Cash Flow

1'000 CHF	1 HY 08	%*	1 HY 07	%*	% YoY
CF from operations**	10'899	13.3%	7'125	8.8%	53.0%
Purchase & proceeds PPE**	-1'798		-789		
Purchase fin. & intangibles**	-179		-343		
Purchase of subsidiaries**	0		-9'414		
CF from investments**	-1'977		-10'546		
FCF prior acquisitions**	8'922	10.9%	5'993	7.4%	48.9%

*: in % of net sales; **: continuing operations only

Strong Balance Sheet

1'000 CHF	30.06.08		31.12.07	
Cash & cash equivalents	62'725		13'367	
Receivables	43'941		57'755	
Inventory	29'600		49'846	
Property, plant & equipment	28'625		57'596	
Financial, intangible & tax assets	45'374		69'004	
Total assets	210'265		247'568	
Payables & short term liabilities	27'441		29'186	
Bank loans & other loans	7'095		36'555	
Other long term liabilities	4'928		16'162	
Equity (equity ratio)	170'801	81.2%	165'665	66.9%
Total liabilities & equity	210'265		247'568	

High Profit from Sale of Medical

1'000 CHF	1 HY 08
Profit after tax discontinued operations 1-4 2008	1'419
Gain after tax on sale of discontinued operations	28'281
Profit from discontinued operations	29'700
Disposed assets discontinued operations	89'014
Disposed liabilities discontinued operations	20'646
Net disposals discontinued operations	68'368
Net cash flow discontinued operations 1-4 2008	1'077
Net cash flow on sale of discontinued operations	93'426
Net cash flow from discontinued operations	94'503
Consideration received, satisfied in cash	102'817
Costs of disposal, satisfied in cash	-4'299
Cash disposed of	-5'092
Net cash flow on sale of discontinued operations	93'426

23

COLTENE Outlook 2008 - Update

Assumptions:

- Dental market consumables sales growth $\geq 3.5\%$
- Forex rate: USD / CHF = 1.05
- Forex rate: EUR / CHF = 1.60

Indications:

- COLTENE Sales CHFm 170
- COLTENE EBIT CHFm 27.5 (16.2%)

Sales growth rates without forex impact 7.5%



24

**Thank you very much
for your attention!**

Q & A